Russell Investments Group, Ltd. Cue Biopharma, Inc. Transaction History

Russell Investments Group, Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	BUY	$1.72 - $3.1 $87 - $158	51 Added 42.15%	172 $0
Q3 2023 Nov 13, 2023	BUY	$2.23 - $4.69 $269 - $567	121 New	121 $0
Q2 2022 Jul 29, 2022	SELL	$2.49 - $5.92 $2,995 - $7,121	-1,203 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$10.06 - $15.3 $617,281 - $938,808	-61,360 Reduced 98.08%	1,203 $17,000
Q2 2021 Aug 04, 2021	BUY	$10.9 - $14.53 $382,949 - $510,482	35,133 Added 128.08%	62,563 $728,000
Q1 2021 May 10, 2021	SELL	$11.2 - $16.09 $262,830 - $377,584	-23,467 Reduced 46.11%	27,430 $333,000
Q4 2020 Feb 08, 2021	BUY	$11.12 - $16.4 $197,346 - $291,050	17,747 Added 53.54%	50,897 $636,000
Q2 2020 Aug 05, 2020	SELL	$12.7 - $30.73 $209,588 - $507,137	-16,503 Reduced 33.24%	33,150 $809,000
Q1 2020 May 06, 2020	SELL	$9.85 - $22.27 $25,413 - $57,456	-2,580 Reduced 4.94%	49,653 $701,000
Q4 2019 Jan 29, 2020	BUY	$7.06 - $17.47 $312,694 - $773,763	44,291 Added 557.68%	52,233 $828,000
Q3 2019 Nov 01, 2019	BUY	$6.78 - $9.28 $53,846 - $73,701	7,942 New	7,942 $67,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.